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Abstract
Background: Acute respiratory failure is the leading reason for intensive care unit (ICU) admission in
immunocompromised patients, and the need for invasive mechanical ventilation has become a major clinical
endpoint in randomized controlled trials (RCTs). However, data are lacking on whether intubation is an objective criteria
that is used unbiasedly across centers. This study explores how this outcome varies across ICUs.
Methods: Hierarchical models and permutation procedures for testing multiple random effects were applied on both
data from an observational cohort (the TRIAL-OH study: 703 patients, 17 ICUs) and a randomized controlled trial (the
HIGH trial: 776 patients, 31 ICUs) to characterize ICU variation in intubation risk across centers.
Results: The crude intubation rate varied across ICUs from 29 to 80% in the observational cohort and from 0 to 86% in
the RCT. This center effect on the mean ICU intubation rate was statistically significant, even after adjustment on
individual patient characteristics (observational cohort: p value = 0.013, median OR 1.48 [1.30–1.72]; RCT: p value 0.004,
median OR 1.51 [1.36–1.68]). Two ICU-level characteristics were associated with intubation risk (the annual rate of
intubation procedure per center and the time from respiratory symptoms to ICU admission) and could partly explain this
center effect. In the RCT that controlled for the use of high-flow oxygen therapy, we did not find significant variation in
the effect of oxygenation strategy on intubation risk across centers, despite a significant variation in the need for invasive
mechanical ventilation.
Conclusion: Intubation rates varied considerably among ICUs, even after adjustment on individual characteristics.
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Background
There is an increasing trend to consider mortality as a
sub-optimal primary endpoint in randomized controlled
trials (RCTs) involving critically ill patients [1–4]. In
acute respiratory failure, the need for invasive mechan-
ical ventilation may appear as a legitimate alternative to
avoid negative RCTs. Indeed, over the last two decades,
strategies to avoid invasive mechanical ventilation and
related complications have been evaluated in patients
with acute hypoxemic respiratory failure [1, 3, 5–7]. This
consideration is even more relevant in immunocom-
promised patients in whom higher mortality rates have
been reported in patients requiring invasive mechanical
ventilation, most particularly in those meeting criteria
for acute respiratory distress syndrome [8, 9]. Thus, non-
invasive ventilation (NIV), continuous positive airway
pressure (cPAP), and the use of high-flow nasal cannula
(HFNC) have been widely explored in this subset of pa-
tients [1, 3, 5–7]. Hence, the need for intubation has be-
come a major clinical endpoint in RCTs of patients with
acute respiratory failure [8, 10–14].
In both cohort studies and RCTs, invasive mechanical
ventilation delivery may however vary across centers,
possibly leading to biased conclusions. This heterogen-
eity in mechanical ventilation use refers to “center ef-
fects,” a concern already explored in the intensive care
setting [15]. Actually, center effects can be divided into
two components: (i) heterogeneity in the distribution of
the study endpoint across centers and (ii) heterogeneity
in the treatment effect on the outcome across centers
known as “treatment by center interaction.” To date, no
study has investigated a potential center effect in studies
of immunocompromised patients with hypoxemic acute
respiratory failure. In the present study, we sought to
identify a center effect about the need for endotracheal
intubation in immunocompromised patients with acute
respiratory failure.
Methods
Centers and patients
This study included adult immunocompromised patients
with hypoxemic acute respiratory failure (ARF) from the
TRIAL-OH cohort and the HIGH randomized con-
trolled trial (RCT). Details of each study have been de-
scribed previously [3, 16]. Firstly, we derived from the
TRIAL-OH study (1011 patients, 17 centers, 2010–2011)
[16] a cohort of hematological patients admitted to ICU
for ARF. We selected patients with the following criteria:
ARF as defined by tachypnea > 30/min, respiratory dis-
tress, SpO2 < 90% at ICU admission, and/or labored
breathing. Exclusion criteria were admission for another
cause, hypercapnia (defined by a PaCO2 > 50mmHg),
and invasive mechanical ventilation before ICU admis-
sion. Secondly, we used the HIGH trial [3], a RCT which
enrolled 776 immunocompromised patients with hypox-
emic ARF in 31 ICUs, in order to compare HNFC to
standard oxygen at day-28 mortality. In both studies, each
participating center has a senior intensivist and a senior
hematologist in site available 24/7 and sharing decisions
of ICU admission [17]. Note that 14 centers were com-
mon in both the TRIAL-OH cohort and the HIGH trial.
The appropriate ethics committees approved each study.
Variables and risk adjustment
The primary outcome was the need for intubation
through ICU stay as a dichotomous variable. In the
TRIAL-OH study, the decision to perform endotracheal
intubation was left to clinicians in charge at each ICU.
In the HIGH trial, the decision to perform endotracheal
intubation was based on predefined criteria, in agree-
ment with current guidelines, including the therapeutic
response and the clinical status (SpO2, respiratory rate,
signs of respiratory distress, and bronchial secretion vol-
ume) [3]. Individual data reported in tables were col-
lected prospectively. ICU-level data (i.e., center
characteristics) were also used in the analysis. In the
TRIAL-OH cohort, these data were assessed as part of
data collection. In the HIGH trial, they were assessed
with a secondary survey from all the participant centers.
Statistical analysis
Continuous variables are described as median and inter-
quartile range (IQR), and categorical variables are sum-
marized by counts (percent).
Patient characteristics at admission were examined at
the patient level in both studies, and the need for intub-
ation was first assessed in each center without adjusting
on potential confounding factors, which is referred as
the “crude need for intubation.” Hierarchical logistic re-
gression models were used to examine the variability on
the outcome between ICUs and the association between
ICU characteristics and the outcome, adjusting for pa-
tient characteristics [18]. To do this, we used the mixed-
effect model with a normally distributed random effect
for ICU (random intercept). Exchangeability was as-
sumed across all providers [5]. In practice, the effect of a
given ICU was modeled through its own regression coef-
ficient, which compares to the crude average need for
intubation across all centers [5, 6]. This allows us to
model between ICU heterogeneity in the average intub-
ation risk. These models provide an estimation of het-
erogeneity in the form of the variance of the random
effects, where the closer the variance is to zero, the
smaller the center effect is. Because it could be hard to
interpret, we computed the median odds ratio (MOR) to
better understand the importance of the center effect on
the mean intubation risk, that is on the same scale as
traditional prognostic factors [6, 7, 18, 19]. Briefly, MOR
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corresponds to the median of all ORs that can be com-
puted between two patients with the same characteristics,
but randomly chosen from two different centers, namely
in a higher risk center and in a lower risk one [6, 18].
MOR quantifies the differences between ICUs. If the
MOR equals 1, then there are no differences in intubation
risk between ICUs.
First, the model was built without any adjustment
(“empty model”), which allows us to investigate a poten-
tial center effect. This unadjusted model contained only
ICU-specific random intercepts. Then, we provided ad-
justment on predefined individual covariates as fixed ef-
fects, without ICU characteristics or interventions.
These covariates were specified a priori as potential con-
founders and included age, comorbidities assessed by
the Charlson comorbidity index, type of immunosup-
pression (in three classes, malignant hemopathy, solid
cancer, and others), previous allogeneic stem cell trans-
plantation, performance status > 2 (bedridden or
dependent), severity of illness with SOFA score without
respiratory item, Pa02/FiO2 ratio in four categories (>
300, 200–300, 100–200, ≤ 100 mmHg, with > 300 mmHg
as reference), respiratory rate > 30 /min, and ARF diag-
nosis. This model was used to estimate adjusted ICU
random effects, because we were interested in studying
heterogeneity in outcomes. ICU were then ranked by
their estimated random effect on intubation risk (ad-
justed for patient characteristics only) and classified into
quartiles. For descriptive purposes, patient and ICU
characteristics were compared across quartiles of the
risk-adjusted intubation rate, using the Cochran–Man-
tel–Haenszel row mean score test and nonzero correl-
ation test for testing the difference for categorical and
continuous variables, respectively. To illustrate the mag-
nitude of the effect of center on intubation risk, we per-
formed conditional standardization of the regression
results for a given patient with median and modal values
for the covariates in the patient-level adjusted model.
Last, hospital- and ICU-level covariates (center volume,
annual volume of ID in ICU, annual rate of IMV pa-
tients defined by the number of patients with IMV/num-
ber of admission, academic status of hospital) were
entered in the model as fixed effects and reported in
terms of odds ratios, in order to try to explain the dis-
crepancies between center. Because the time since re-
spiratory symptoms onset and ICU admission could
reflect local practices, it was considered as an ICU-level
characteristic in the analysis.
To test for the significance of the center effects
(empty model and model adjusted on patient and
center characteristics), we used permutations test, a
recommended approach to test for random effect
[20–23]. More details about the methods used are
given in the Additional file 1.
These methods were applied in both the observational
cohort and the RCT, separately.
Sensitivity analyses
Primary analyses were performed on the complete cases,
assuming missing completely at random covariates.
Then, sensitivity analyses for such assumptions were
performed, based on multiple imputation with chained
equation [24]. We performed exploratory subset ana-
lyses, restricting ourselves to patients with full code sta-
tus, in patients with malignant diseases in the HIGH
trial and after exclusion of ICUs with extreme size (ICUs
> 20 beds or ICUs< 8 beds). In the HIGH trial, we also
investigated the center heterogeneity in the prognostic
effect of the oxygenation strategy which was randomly
assigned (HFNC or standard oxygen). This was not pos-
sible in the observational cohort due to allocation bias.
To do this, we introduced two random effects in the pa-
tient-level adjusted model for each center: a random ef-
fect on the mean intubation (random intercept) risk as
previously described and a random effect on the effect of
the oxygenation strategy (with standard oxygen as refer-
ence) on intubation risk random slope. This allows us to
model centers’ variability not only on the average intub-
ation risk but also on the effect of the oxygenation strat-
egy on the need for intubation. We then applied
permutation test to investigate for significance of center
effect [20, 22].
All reported p values are two-sided; p < .05 was consid-
ered statistically significant. All analyses were performed
using R version 3.1.0 (R Foundation for Statistical Com-
puting [http://www.R-project.org/]).
Results
Patients
Overall, 703 patients (age 61.0 years [51.0–71.0], 61.0%
male) were included in the observational cohort and 776
patients (age 64.0 years [56.0–71.0], 66.2% male) from
the HIGH trial (Additional file 1: Figure S1). Table 1 re-
ports the main characteristics at ICU admission and the
respiratory parameters at baseline. As shown, the main
cause of immunosuppression was hematological malig-
nancies in both studies (94% in the observational cohort
and 45% in the RCT). Most of the patients were admit-
ted from ward with a good performance status (i.e., 0–2)
over the 3months preceding ICU admission (78.8% and
63.7% respectively). Sequential Organ Failure Assess-
ment (SOFA) score at admission was 6 [3, 4, 8–12, 25]
and 6 [4, 8–10, 25] the in cohort and trial respectively.
In both studies, the main diagnosis of ARF was bacterial
infection (269 (38.2%) in the Trial-OH cohort, 355
(45.7%) in the HIGH trial) followed by opportunistic
germ infections (89 (12.6%) and 93 (12.0%)).
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Table 1 Characteristics of patients at ICU admission
Demographic and clinical data Trial-OH cohort (n = 703) High randomized controlled trial (n = 776)
Characteristics of the patients
Demographics
Age, median [IQR], years 61 [51.0–71.0] 64.0 [56.0–71.0]
Male sex, n (%) 429 (61.0) 517 (66.2)
BMI, kg/m2 24.6 [21.6–27.7] 24.9 [22.3–28.1]
Source of admission
ER or ambulance 298 (42.4) 327 (42)
Night or weekend admissions 434 (61.7)
Comorbidities
Respiratory 199 (28.3) 242 (31.2)
Heart failure 98 (14) 50 (6.4)
Kidney disease 64 (9) 97 (12.5)
Charlson score 4 [3.0–6.0] 5.0 [3.0–7.0]
Underlying conditions
Hematologic malignancies 665 (94.6) 348 (45)
Solid tumors 38 (5.4) 265 (34)
Immunosuppressive drugs – 268 (35)
Remission of malignancy 293 (41.7) 141 (18.2)
Autologous stem cell transplantation 104 (14.8) 48 (6.2)
Allogeneic stem cell transplantation 113 (16.1) 61 (7.9)
Poor performance status (> 2) 149 (21.2) 282 (36.3)
Clinical parameters at baseline
Respiratory rate, breaths/min 32 [26.0–38.0] 28.0 [23.0–33.0]
Oxygen flow, l/min 6 [3.0–10.0] 11.0 [6.0–15.0]
Glasgow coma score 15 [15.0–15.0] 15.0 [15.0–15.0]
Neutropenia 203 (28.9) 136 (17.5)
Number of quadrants on chest X-ray 2.0 [1.0–4.0] 2.0 [2.0–4.0]
Arterial blood gas at baseline
pH, units 7.40 [7.31–7.46] 7.43 [7.39–7.47]
PaCO2, mmHg 37.0 [31.0–44.0] 35.0 [30.5–39.0]
PaO2/FiO2 ratio, mmHg 161.4 [113.0–226.4] 132.0 [93.0–176.0]
Severity of PaO2/FiO2 ratio at baseline
PaO2/FiO2 > 300mmHg 100 (14.2) 38 (4.9)
PaO2/FiO2 200–300mmHg 125 (17.8) 104 (13.4)
PaO2/FiO2 100–200mmHg 340 (48.4) 351 (45.2)
PaO2/FiO2 ≤ 100mmHg 138 (19.6) 231 (29.8)
Organ dysfunction at day 1
SOFA score without respiratory item 5.00 [3.0–8.0] 3.00 [3.0–4.0]
Use of vasopressor 225 (32.0) 117 (15)
ARF etiology
Bacterial infection 269 (38.2) 355 (45.7)
Opportunist germs infection 89 (12.6) 93 (12.0)
Disease-related infiltrates/drug-related toxicity 73 (10.4) 92 (11.9)
Cardiogenic pulmonary edema 58 (8.2) 8 (1.0)
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ICU and hospital mortality rates were 32.4% (228 deaths)
and 44% (309 deaths) in the cohort and 31.6% (245 deaths)
and 41.5% (322 deaths) in the trial, respectively.
Center effect on endotracheal intubation risk
Patient-level analysis
Center size distribution is summarized in Additional file 1:
Table S1 and S2. In the TRIAL-OH cohort, the crude in-
tubation rate was 57% (398 patients, median delay of 0 day
[0–1]) and ranged from 29 to 80% across ICUs. In the
HIGH trial, the crude intubation rate was 41.5% (320 pa-
tients, 1 day [0–2]) and ranged from 0 to 86% in the differ-
ent participating centers (Fig. 1). Of note, 45% (181
patients) of intubation procedure were performed during
nighttime or weekend in the TRIAL-OH cohort and 56%
(181 patients) in the HIGH trial.
In both studies, we found a significant variation in the
crude intubation risk across ICUs (TRIAL-OH cohort
and HIGH trial, p < 0.01). Median OR for baseline intub-
ation risk were 1.38 [1.24–1.56] and 1.37 [1.26–1.50],
respectively.
We then performed multivariable analyses to adjust on
individual potential confounders for endotracheal intub-
ation. As shown in Table 2, in both studies, there was a sig-
nificant center effect on intubation risk after adjustment
on potential individual confounders (TRIAL-OH co-
hort, p value 0.013; HIGH trial, p value 0.004). The
magnitude of the center effect is depicted in Fig. 1 a and b.
As shown, there was a significant variation of intubation
Table 1 Characteristics of patients at ICU admission (Continued)
Demographic and clinical data Trial-OH cohort (n = 703) High randomized controlled trial (n = 776)
Undetermined 100 (14.2) 176 (22.7)
Others 104 (14.8) 103 (13.3)
NA 10 (1.4) 2 (0.3)
Outcome
Invasive mechanical ventilation 398 (57) 320 (41.5)
ICU mortality 228 (32.4) 245 (31.6)
Hospital mortality 309 (44.0) 322 (41.5)
ICU length of stay 6.0 [3.0–12.0] 7.0 [4.0–13.5]
Hospital length of stay, days 15.0 [7.0–29.0] 26.0 [15.0–42.0]
Values are given in N (%) or median [IQR]
Abbreviations: IQR interquartile range, ICU intensive care unit, SOFA Sequential Organ Failure Assessment, BMI body mass index, mo months
Fig. 1 Crude intubation rate by center (left) and distribution of center effects on intubation rate (right) adjusted on individual confounders.
Centers are sorted by study size. Black squares represent adjusted center effects on the mean intubation risk as odds ratio (OR) (comparison of
each center to a theoretical average reference center with OR = 1). a The TRIAL-OH cohort. b The HIGH trial. Abbreviations: IMV invasive
mechanical ventilation, OR odds ratio
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risk among the different participant ICUs. Median OR for
center effect on the mean intubation risk were 1.48 [1.30–
1.72] (TRIAL-OH cohort) and 1.51 [1.36–1.68] (HIGH
trial). In other words, the center effect persisted after ad-
justment for individual patient characteristics.
Also, given exact same baseline prognostic factors, the
predicted intubation risk of two patients selected in differ-
ent ICU ranged from 46 to 70% in the TRIAL-OH cohort
and from 28 to 55% in the HIGH trial (Table 2 and Fig. 2).
ICU-level analysis
Differences in patient and hospital characteristics and
outcomes by hospital-adjusted intubation rate quartiles
are illustrated in Additional file 1: Tables S3-S6 and
Figure S2. As expected, baseline patient characteristics
were well balanced between the groups after case-mix
adjustment. Nonetheless, in both TRIAL-OH cohort and
HIGH trial, patients treated at ICU in the higher quar-
tiles (Q3 and Q4) of intubation risk were more likely to
have a good performance status. At the ICU level, the
only difference was the annual rate of patients whom re-
quired invasive mechanical ventilation. We then adjusted
the analysis on ICU-level characteristics. Table 3 pre-
sents intubation risk as a function of ICU characteristics.
As shown, the annual IMV rates and the time from re-
spiratory symptoms onset to ICU admission were both
associated with a greater risk for intubation. Adjustment
on these two factors significantly reduces the variability
in the intubation risk which was no longer significant
(Additional file 1: Figure S3).
Table 2 Results of the multivariable mixed regression model with center effect on subsequent risk for endotracheal intubation
Trial-OH cohort High randomized controlled trial
No. of intubation/no. of observation 398/703 320/776
Center effect*
Estimated true inter-hospital variance** 0.156 0.186
Median odds ratio*** 1.48 [1.30–1.72] 1.51 [1.36–1.68]
Predicted probability of intubation, mean (min-max) across centers 0.56 (0.46–0.70) 0.41 (0.28–0.55)
p value for center effect 0.013 0.004
*Results were adjusted on age, Charlson comorbidity index, type of immunosuppression, allogeneic stem cell transplantation, sex, performance status > 2,
diagnosis of acute respiratory failure, Pa02/FiO2 ratio in four categories (> 300, 200–300, 100–200, ≤100 mmHg, with > 300 mmHg as reference), respiratory rate >
30/min, SOFA score without respiratory item
**Intercept variance
***The median odds ratio (MOR) is defined as the median value of the odds ratio between the hospital at highest risk and the hospital at lowest risk for two
randomly chosen hospitals
Fig. 2 Absolute risk of intubation according to center calculated with the use of conditional standardization of the regression results. Adjusted
conditional risk of intubation (with 95% confidence intervals) shows the predicted risk of intubation for a patient at approximately the 50th
percentile of risk in each center—for example, in the HIGH trial, a 64-year-old patient with hematologic malignancy, a Charlson score at 5,
performance status < 2, and a SOFA score without respiratory item at 3 who was admitted for bacterial pneumonia with a PaO2/Fi02 between
100 and 200 and a respiratory rate at 30/min
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Sensitivity analyses
In the HIGH trial, we investigated the effect of center
not only on the average intubation risk but also on the
intervention arm effect (HFNC use). As previously de-
scribed, a global test found a significant center effect (p
value 0.037) on the mean risk for intubation. However,
we did not find any significant between-center hetero-
geneity of the effect of HFNC use on subsequent intub-
ation risk (p value 0.188, Additional file 1: Figure S4).
This suggests that the effect of treatment on survival did
not vary across centers, but that a significant heterogen-
eity in the distribution of outcomes was reported.
To explore how stable were these findings, we re-
peated the analysis under varying assumptions. Exclud-
ing ICUs with extreme sizes did not change our results
(p value for center effect 0.013 (TRIAL-OH cohort) and
0.003 (HIGH trial). In the HIGH trial, our results were
not affected by the exclusion of patients with “do-not-in-
tubate order” through ICU course (34 patients excluded,
p value for center effect 0.005) or when we restricted
our analysis to onco-hematological patients only (613 pa-
tients, p value for center effect 0.028). Finally, analyses per-
formed after multiple imputation of missing data led to the
same results (TRIAL-OH cohort, p value for center effect
0.012, median OR 1.41 [1.26–1.61]; HIGH trial, p value for
center effect < 0.01, median OR 1.36 [1.25–1.47]).
Discussion
This study was the first to explore variability across
centers of the risk for invasive mechanical ventilation
in critically ill immunocompromised patients with
ARF. The significant variability in intubation rates ap-
plies to both a large observational cohort and a large
randomized controlled trial. Moreover, the significant
variability persisted after adjustment on potential indi-
vidual confounders for IMV. Furthermore, the magni-
tude of the center effect, summarized herein with the
median OR, was quite large. Last, we identified two
ICU-level characteristics which could partly explain
the observed discrepancy.
These findings suggesting between-center heterogen-
eity in intubation risk raise several concerns. In im-
munocompromised patients, ARF is the leading cause
for ICU admission, the need for IMV being near 50%
and mortality rates reaching up to 70% [26–28]. Also,
strategies to improve oxygenation and avoid invasive
mechanical ventilation have received a great attention
over the last two decades [29, 30]. It is generally admit-
ted that an ideal trial endpoint should be clinically rele-
vant, accepted in medical practice, and sensitive and
specific to detect the anticipated effect of the treatment
[31]. In the ICU setting, mortality has long been a major
criterion. However, numerous RCTs were deemed nega-
tive because of the inappropriateness of the primary
endpoint [32]. As a consequence, the need for endo-
tracheal intubation could appear as a better target in
ARF and has become the commonest primary endpoint
of more recent RCTs [8, 10, 25]. However, in this study,
we found that the adjusted intubation risk ranged from
46 to 70% in an observational study and from 28 to 55%
in a RCT. Hence, evidences for a significant variation in
intubation rate across different ICUs could challenge the
validity of such outcome.
Different reasons could be argued to explain these dis-
crepancies: First, organizational practices and local ad-
mission policies. In this study, we found that intubation
risk increased with the annual ratio of patient with IMV
in a given center, and the time from respiratory symp-
tom onset to ICU admission. One could suppose that
these two factors could reflect local practices for ICU
admission and IMV initiation. Second, physician experi-
ence as well as patient conditions could influence the in-
tubation decision [33]. This point is hard to capture in
statistical analysis, but in our study, we found a signifi-
cant variation in intubation rate despite predefined
intubation criteria. Moreover, most of intubation proce-
dures have been made during out of hour period, sup-
porting the importance of workload and personal
practice factors. In a study which focused on IMV initi-
ation in septic shock patients, de Montmollin et al.
Table 3 Intensive care unit characteristics associated with intubation risk
Hospital characteristics Trial-OH cohort High randomized controlled trial
OR* [95% CI] p value OR* [95% CI] p value
Teaching hospital 1.04 [0.55; 1.96] 0.89 0.84 [0.46;1.52] 0.56
No. of hospital beds, per 100 beds 0.99 [0.94; 1.04] 0.77 0.94 [0.87;1.01] 0.11
No. of ICU beds, per 10 beds 0.96 [0.83; 1.12] 0.67 0.93 [0.66;1.31] 0.70
Annual volume of ID patients 0.95 [0.75; 1.22] 0.72 1.00 [0.81;1.23] 0.99
Annual IMV rate 1.26 [1.04; 1.53] 0.01 1.28 [1.02;1.62] 0.03
Time from respiratory symptoms to ICU admission, by day 1.08 [1.02; 1.15] 0.005 1.10 [1.02; 1.87] 0.02
*Results were adjusted on age, Charlson comorbidity index, type of immunosuppression, allogeneic stem cell transplantation, sex, performance status> 2,
diagnosis of acute respiratory failure, Pa02/FiO2 ratio in four categories (> 300, 200–300, 100–200, ≤100 mmHg, with > 300 mmHg as reference), respiratory rate >
30 /min, SOFA score without respiratory item
Abbreviations: ICU intensive care unit, ID immunocompromised patients, IMV invasive mechanical ventilation
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found a good agreement in a panel of intensivist for hyp-
oxemia and respiratory rate as criteria for the need of in-
tubation [34]. However, in our study, discrepancies
persisted after adjustment on these factors. These two
points encourage the need for define consensual intub-
ation criteria, as it appears to date as an important out-
come. Last, patient severity is an important factor and
could vary across centers, but in the present study, a sig-
nificant center effect on intubation risk persisted even
after adjustment on individual confounders.
These findings emphasize the need for several consid-
erations. First, mortality is probably an unrealistic out-
come in an era of numerous negative trials and
endotracheal intubation appears to suffer for large
center-related source of variation due to case-mix het-
erogeneity and more importantly local practices. Non-
mortal outcome such as patients reported outcome or
variation of severity parameters (delta-SOFA or oxygen-
ation parameters) could be taken into consideration for
future trials [32]. Then, in observational studies and
maybe RCT, it could be of importance to take into ac-
count between center variation in analysis. In this way,
the random-effect logistic model could be of interest
[35, 36]. Finally, the large variation in endotracheal rate
across centers despite adjustment on individual character-
istics and patient severity could suggest variation in the
decision of endotracheal intubation. As it remains an im-
portant outcome in clinical studies, there is maybe the
need for a consensual definition of IMV implementation.
This study has several limitations. First, it was a post
hoc analysis and we cannot rule the inherent limitations
of these methods. However, using adequate statistical
methods, we found significant center variations in intub-
ation risk, identified potential explicative factors, and
assessed its importance. Second, although we attempted
to address ICU variation by adjusting for patient-level
clinical factors known to be related with intubation risk,
but the possibility of confounding by unmeasured covari-
ates remains. Third, we used data from two studies
performed in specialized centers. This could limit the
generalizability of the results. Last, we cannot exclude that
some of the patients could have been intubated for non-
respiratory reasons (i.e., coma, severe shock, or copious
tracheal secretions). However, our record of non-respira-
tory SOFA and the adjustments that were made in the
analyses actually takes into account this issue.
Conclusion
Invasive mechanical ventilation has become an import-
ant endpoint in immunocompromised patients with
acute respiratory failure. However, we found significant
variation in intubation risk across ICU in both an obser-
vational cohort and a randomized controlled trial. Our
results highlight the need to take into account center
effect in analysis because it could be an important con-
founder. Reasons for heterogeneity are various (case-mix
differences, center practices). This gives opportunities to
future improvement in care management and study
design.
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